ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential
AbstractHighly selective N-type voltage-gated calcium (CaV) channel inhibitors from cone snail venom (the ω-conotoxins) have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Earlier in 2005, Prialt (Elan) or synthetic ω-conotoxin MVIIA, was the first ω-conotoxin to be approved by Food and Drug Administration for human use. This review compares the action of three ω-conotoxins, GVIA, MVIIA and CVID, describing their structure-activity relationships and potential as leads for the design of improved N-type therapeutics that are more useful in the treatment of chronic pain. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Schroeder, C.I.; Lewis, R.J. ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential. Mar. Drugs 2006, 4, 193-214.
Schroeder CI, Lewis RJ. ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential. Marine Drugs. 2006; 4(3):193-214.Chicago/Turabian Style
Schroeder, Christina I.; Lewis, Richard J. 2006. "ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential." Mar. Drugs 4, no. 3: 193-214.